Verastem VSTM 深 滬
已收盤 08-07 16:00:00 美东时间
6.74
+0.830
+14.04%
華盛通- 最 高7.10
- 今 開6.65
- 成交量 431.90万股
- 最 低 6.02
- 昨 收 5.91
- 總市值 5.92亿
- 52周最高 11.245
- 市盈率 靜 --
- 換手率 4.92%
- 52周最低 3.43
- 委 比 98.28%
- 總股本 8787.36万
- 歷史最高 225.84
- 量 比 2.49
- 振 幅 18.27%
- 歷史最低 2.10
- 每 手 1
- 風險率 1.92%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Guggenheim Maintains Buy on Verastem, Lowers Price Target to $12
Guggenheim analyst Michael Schmidt maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price target from $14 to $12.
08-08 00:46
Verastem shares are trading higher after the company reported better-than-expected Q2 financial results.
Verastem shares are trading higher after the company reported better-than-expected Q2 financial results.
08-07 04:56
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why
The Russell 2000 opened the second half of 2026 pinned near a record around 3,000, going almost nowhere since the first half closed. Underneath that flat tape, seven small caps ripped 28% or more in just four trading sessions. The index, as tracked by the iShares Russell 2000 ETF (NYSE:IWM), is comi...
07-22 03:52
劲方医药-B盘中涨超7% 拟配股净筹约4.67亿元
劲方医药-B（02595）盘中涨超7%，截至发稿，股价上涨4.99%，现报40.34港元，成交额1.16亿港元。 劲方医药拟配售1，360万股新H股，每...
07-15 10:15
美股大行评级 | 最高800美元！16家大行首予SpaceX"买入"或"超配"评级；奥本海上调康宁目标价从210美元升至230美元
今日重点评级关注：Canaccord Genuity：维持AtaiBeckley"买入"评级，目标价从15美元升至17美元；Truist Securities：维持NUVATION BIO"买入"评级，目标价从12美元升至13美元
07-08 15:31
RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $14
RBC Capital analyst Leonid Timashev maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers the price target from $15 to $14.
07-08 00:19
美股大行评级 | 瑞银上调超微公司目标价从455美元升至670美元，上调ARM目标价从260美元升至470美元；美银证券上调台积电目标价从490美元升至590美元
今日重点评级关注：Jones Trading：维持Definium Therapeutics"买入"评级，目标价从61美元升至74美元；韦德布什：维持Cerebras Systems"跑赢大市"评级，目标价从270美元升至280美元
06-25 11:32
BTIG Reiterates Buy on Verastem, Maintains $18 Price Target
BTIG analyst Jeet Mukherjee reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $18 price target.
06-24 18:02
Verastem Oncology Data From TARGET-D 101 Phase 1/2 Clinical Study Of VS-7375 Shows Encouraging Clinical Activity Including Favorable Safety Profile; Broad Anti-Tumor Activity Observed
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive preliminary data from the ongoing TARGET-D 101 Phase 1/2 clinical trial evaluating VS-7375, an investigational oral KRAS G12D ...
06-24 04:03
Verastem Oncology Doses First Participant In Its TARGET-D-201 Phase 2 Registration-Directed Study Of VS-7375 To KRAS G12D-Mutated Metastatic Pancreatic Ductal Carcinoma
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been dosed in the TARGET-D 201 Phase 2 registration-directed trial (NCT07644559) evaluating VS-7375, an inve...
06-17 04:02
